A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Latest Information Update: 05 Feb 2025
At a glance
- Drugs Navacaprant (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms KOASTAL-1
- Sponsors Neumora Therapeutics
Most Recent Events
- 30 Jan 2025 Status changed from active, no longer recruiting to completed.
- 09 Jan 2025 Planned End Date changed from 1 Jul 2025 to 1 Jan 2025.
- 09 Jan 2025 Status changed from recruiting to active, no longer recruiting.